NRXP - NASDAQ
NRx Pharmaceuticals, Inc.
$4.13
+2.1%NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
At a Glance
Live SnapshotNRx Pharmaceuticals, Inc. Management Team
Mr. Matthew Patrick Duffy
Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics
Compensation
$338,000
Mr. Michael S. Abrams
Chief Financial Officer
Dr. Riccardo Panicucci Ph.D.
Chief Manufacturing & Technology Officer
Compensation
$240,000
Dr. Philip T. Lavin Ph.D.
Chief Methodologist
Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer
Compensation
$825,000
Suzanne Messere
Investor Relations
NRx Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for NRXP.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
NRXP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | February 23, 2026 | March 23, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | September 05, 2024 | October 08, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | March 11, 2024 | March 21, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 22, 2023 | December 19, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | January 10, 2023 | February 02, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 21, 2022 | July 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 01, 2021 | April 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | December 07, 2020 | December 18, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | July 10, 2020 | July 23, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | March 09, 2020 | March 23, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.